- Shionogi’s third-quarter operating income reached 53.36 billion yen, marking a 31% increase compared to the previous year, surpassing the estimated 42.29 billion yen.
- The company’s net income for the same period was 50.67 billion yen, a rise of 38% year-on-year, beating the expected 42.13 billion yen.
- Net sales achieved 119.63 billion yen, up by 13% from the prior year, exceeding the forecasted 112.09 billion yen.
- For the full year forecast, Shionogi maintains its outlook with projected operating income at 165.00 billion yen, slightly above the estimated 162.36 billion yen.
- Net income for the year is expected to be 171.00 billion yen, also higher than the anticipated 166.93 billion yen.
- The company projects net sales to reach 460.00 billion yen, outperforming the estimated 446.55 billion yen.
- Analysts’ recommendations for Shionogi include 7 buys, 8 holds, and 1 sell.
- All comparisons to past results are based on the company’s original reported values.
Shionogi & Co on Smartkarma
Smartkarma analysts, including Tina Banerjee, are closely monitoring Shionogi & Co‘s performance. In a recent report titled “Shionogi & Co (4507 JP): Performance to Improve in H2; Upcoming Drugs to Accelerate Growth,” the analysts shed light on the company’s promising outlook. Shionogi has reaffirmed its FY25 guidance, showcasing better financial results in Q2FY25 and expected growth in H2FY25. Noteworthy developments include acquiring distribution rights for Quviviq and submitting a New Drug Application (NDA) for zuranolone in Japan. These strategic moves are poised to boost revenue streams and position Shionogi for future success.
Furthermore, Shionogi’s focus on expanding its overseas business and leveraging royalty income reflects a robust foundation for sustained growth. With Quviviq offering enhanced efficacy, safety features, and a substantial patient base, it is anticipated to be a key revenue driver for the company. Moreover, the NDA submission for zuranolone, a potential treatment for major depressive disorder, signals exciting prospects with an anticipated approval in H1FY26. Smartkarma’s insightful coverage of Shionogi & Co highlights the company’s strategic advancements and potential for accelerated growth in the pharmaceutical sector.
A look at Shionogi & Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shionogi & Company Ltd., a pharmaceutical giant, shows a promising long-term outlook based on its Smartkarma Smart Scores. With a solid score in Value and Dividend at 3, the company demonstrates a fair valuation and willingness to reward investors. Moreover, scoring a noteworthy 4 in Growth and Resilience, Shionogi & Co seems poised for sustainable expansion and resilience in challenging times. The company’s Momentum score of 5 further strengthens its outlook, indicating strong positive price trends and market favorability. Combining these factors, Shionogi & Co‘s overall prospective performance appears robust.
In summary, Shionogi & Co is a pharmaceutical powerhouse focusing on developing both prescription and over-the-counter drugs along with diagnostic solutions. With a balanced set of Smartkarma Smart Scores – Value 3, Dividend 3, Growth 4, Resilience 4, and Momentum 5 – the company showcases a well-rounded profile with favorable indicators for long-term success in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
